Related Experiment Videos
Insights
Most acute hepatitis B virus infections resolve naturally. However, a small percentage develop chronic hepatitis B, increasing risks for liver disease and immune disorders.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Acute HBV infection resolves spontaneously in the majority of cases.
- A minority of individuals develop chronic hepatitis B, leading to long-term health risks.
Purpose of the Study:
- To summarize the natural course of acute hepatitis B virus infection.
- To highlight the risks associated with chronic hepatitis B carriers.
- To mention current and developing treatment strategies.
Main Methods:
- This is a summary of existing knowledge and clinical observations.
- No new experimental data were generated.
Main Results:
- Approximately 95% of acute hepatitis B virus infections resolve within one year.
- The remaining 5% progress to chronic hepatitis B, becoming carriers.
- Chronic carriers face elevated risks for immune-complex disorders and liver diseases.
Conclusions:
- Chronic hepatitis B represents a persistent public health challenge.
- Interventions focus on reducing vertical transmission and viral replication.
- Ongoing research explores immunosuppressive and antiviral therapies for chronic carriers.
Abstract:
Acute hepatitis B virus infection resolves in 95 percent of patients within one year. The remaining 5 percent have persistent infection and become chronic carriers. In the United States, there are nearly one million carriers, who are at increased risk of developing immune-complex disorders and liver diseases. Treatment is available to reduce vertical transmission, and ongoing trials of immunosuppressive and antiviral agents are aimed at decreasing or resolving viral replication.